Amid the cool capital markets climate, the recent surge in billion-dollar M&A deals involving overseas biomedical companies acquiring smaller Chinese counterparts have paved a path for early investors of China enterprises to make returns. Since last year, the mainland has seen large-scale cross-border biomedical M&A transactions involving pharmaceutical giants, including AstraZeneca and Novartis. In December